The knockout (KO) of mutant NPM1 from AML cells, using CRISPR-Cas9 gene editing, significantly eliminates the sensitivity of the leukemic cells to menin, exportin-1 inhibitors and cytarabine [113], indicating the presence of a therapeutic window for these substances. The gene discussed is XPO1; the disease is acute myeloid leukemia.